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Abstract  30 
Aims: To determine the prevalence of endometriosis in epithelial ovarian cancers 31 
(EOC) and the association among their histological subtypes and with endometrial 32 
carcinoma. 33 
Methods: An observational cohort study performed in 192 patients operated on for 34 
EOC, 30 women with atypical endometriosis and 17 with p53 positive endometriosis. 35 
Data on associated endometriosis and endometrial carcinomas, histological subtypes, 36 
tumor stage, clinical and pathological characteristics and survival were analyzed.  37 
Results: Twenty cases of EOC (10.4%) had also endometriosis (12.7% in borderline 38 
and 9.3% in invasive cases), being a synchronous finding in most cases. Endometriosis 39 
associated with serous or mucinous EOC was observed in 2.2 and 2.7% of cases 40 
respectively. However, this association was observed in 50% of endometrioid and 23% 41 
of clear cell EOC. Age, parity and tumor stage were lower in endometriosis-associated 42 
EOC patients; and all associated cases were type I (Kurman and Shih’s classification) 43 
and showed better results in survival rate. Endometrial carcinoma was more frequently 44 
associated with endometrioid EOC (25%). 45 
Conclusions: There is a significant association between endometriosis, including 46 
atypical forms, and endometrioid and clear cell carcinomas, but not with other EOC 47 
histotypes. The presence of endometriosis in EOC suggests a better prognosis and an 48 
intermediate stage within the progression endometriosis-carcinoma. 49 
 50 
 51 
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Text 52 
Introduction 53 
Sampson [1] first described the association between endometriosis and ovarian cancer, 54 
and his criteria are still used to identify malignant tumors that arise from endometriosis. 55 
Scott [2] further defined the diagnosis of an endometriosis-associated ovarian carcinoma 56 
stating that benign endometriosis should be contiguous with malignant tissue. This 57 
association has later been reported in several studies [3-7], particularly for 58 
endometriosis with ovarian endometrioid and clear cells carcinomas, suggesting that 59 
concurrent endometriosis is generally associated with a better prognosis for these 60 
specific subtypes of EOC [8-10]. Moreover, atypical endometriosis has been described 61 
as a precursor lesion that can lead to certain types of ovarian cancer [12-16]. Other 62 
authors have also suggested a hormonal dependence or a relationship with other 63 
hormone-dependent pathologies in this type of association [17-18]. Endometriosis-64 
induced inflammation and the auto- and paracrine production of sex steroid hormones 65 
could contribute to ovarian tumor genesis because these changes provide a 66 
microenvironment that favors the accumulation of sufficient genetic alterations and 67 
endometriosis-associated malignant transformation [16]. So, Wei et al. [16] have 68 
suggested that this pathophysiological progression begins with atypical epithelial 69 
proliferation (atypical endometriosis and metaplasia), followed by well-defined 70 
borderline tumors and culminating in malignant ovarian cancer. However, although 71 
some cases of endometriosis-associated ovarian carcinomas appear to be the final 72 
consequence of this pathological progression, the development and neoplastic 73 
transformation is usually controversial, and the epidemiological findings on the 74 
association are still elusive [6,19]. The aims of this study were to determine the 75 
prevalence of endometriosis in all cases of histopathologically confirmed EOC (both 76 
invasive and borderline) operated on by our group within the last 20 years, and to 77 
analyze the relation with different histological subtypes of EOC and endometriosis, 78 
evaluating a possible pathological progression in our patients. The relationship between 79 
these pathologies and endometrial carcinoma was also considered. 80 
 81 
 Materials and Methods 82 
We reviewed the medical charts of 192 patients with EOC (borderline and malignant 83 
carcinomas) who were operated on in our service from 1993 to 2013. Patient clinical 84 
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characteristics, tumor markers, tumor histology and staging, associated pathology, 85 
surgery performed, postoperative clinical course and data for survival analysis were 86 
collected. It was also collected the presence and type of endometriosis when it was 87 
associated with an EOC, as well as the association with other malignant tumors 88 
especially endometrial carcinoma and breast cancer.  89 
EOC patients were grouped by histological types: 1) Serous, 91 cases [32 low grade 90 
serous papillar or borderline, and 59 invasive high grade serous carcinomas]; 2) 91 
Mucinous, 37 cases [22 mucinous borderline, and 15 mucinous invasive]; 3) 92 
Endometrioid, 28 cases [7 pure endometrioid: 3 borderline and 4 invasive;  21 mixed 93 
with endometrioid: 3 borderline and 18 invasive];  4) Clear cells carcinoma, 13 cases [9 94 
pure clear cells: 2 borderline and 7 invasive; 4 mixed of clear cells and endometrioid: 1 95 
borderline and 3 invasive]; and 5) Other mixed and undifferentiated carcinomas (20 96 
cases) and 3 cases of ovarian carcinosarcomas. 97 
In this study, endometriosis-associated ovarian carcinoma was defined by the presence 98 
of ovarian cancer and endometriosis in the same or contralateral ovary or extraovarian 99 
pelvic endometriosis. So, endometriosis was identified when the tissue resembling 100 
endometrial stroma surrounding epithelial glands was present in ovaries or peritoneum. 101 
Besides, atypical endometriosis was considered according to the criteria from Thomas 102 
and Campbell [20] based on the features that were identified in histological 103 
examinations (i.e., large hyperchromatic or pale nuclei with moderate-to-marked 104 
pleomorphism, increased nuclear-to-cytoplasmic ratio, cellular crowding and 105 
stratification) and p53 positive expression. According to these criteria, we identified 20 106 
of the 192 patients as having endometriosis, which was diagnosed as atypical in 5 cases. 107 
With the intention to analyze the significance of the atypical endometriosis associated or 108 
not to EOC, we also reviewed the medical charts of other 47 patients operated on for 109 
endometriosis of which 30 were diagnosed as atypical endometriosis and 17 as typical 110 
endometriosis but p53 positive. These 47 cases reported by the Pathology Service 111 
within the period of study were all operated on after 1999. 112 
Based on a dualistic model of carcinogenesis and Kurman and Shih´s classification [21-113 
22], we divided our EOC cases into two groups: 1) Type I tumors comprising borderline 114 
and low grade serous carcinomas, mucinous, endometrioid, clear cells and transitional 115 
cell carcinomas. 2) Type II tumors comprising high grade serous cancer, malignant 116 
mixed mesodermal tumors and undifferentiated carcinomas. The clinical and 117 
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pathological characteristics as well as the actuarial survival of the different subtypes, 118 
with or without associated endometriosis, were compared. 119 
Statistical analysis was performed using SPSS-15 and 21 (IBM, Spain), RSigma (Systat 120 
Software, San Jose, California, USA) and PEDro (Physiotherapy Evidence Database, 121 
Sidney, Australia) software. Comparison of independent means (Student’s T-test), 122 
comparison of two proportions (relative risk –RR-), a 95% confidence interval (CI) and 123 
the chi-squared test were used to compare the groups. Data are expressed as 124 
percentages, mean ± standard deviation, mean standard error (mse) and minimum and 125 
maximum values. The actuarial survival was analyzed to all EOC groups after 2, 5 and 126 
10 years of follow-up according to the Kaplan-Meier method of estimated survival. All 127 
p values reported are 2-tailed and p <0.05 was considered significant.  128 
 129 
Results 130 
Twenty cases of EOC (10.4%) were associated with endometriosis, 5 of which involved 131 
atypical endometriosis. As shown in Table 1, synchronous endometriosis was found in 8 132 
of 63 patients with borderline or low grade tumors (12.7%) and in 12 of 129 invasive 133 
cases (9.3%), but difference was not significant. Atypical endometriosis was more 134 
frequent in the cases of endometrioid invasive cancer. Synchronous endometrial 135 
carcinoma was also observed in 5 (7.9%) of the borderline tumors and in 7 (5.4%) of 136 
the invasive cases, without significant differences. 137 
Table 2 shows the distribution of endometriosis and endometrial carcinoma among the 138 
different histological subtypes of EOC. Association of endometriosis with serous or 139 
mucinous EOC was observed in 2.2% and 2.7% respectively, and only in borderline or 140 
low grade tumors. However, most of the EOC with subtype endometrioid (71%) or 141 
mixed with predominant endometrioid component (43%) showed associated 142 
endometriosis, mainly in the borderline cases. In the clear cell carcinomas, associated 143 
endometriosis was observed only in the invasive cases (43%); it was not present in the 144 
mixed endometrioid+clear cell or mixed clear cell carcinomas. Nor endometriosis was 145 
observed in the other mixed subtypes, high grade invasive, carcinosarcomas and 146 
undifferentiated carcinomas. The association of endometriosis with endometrioid, mix-147 
endometrioid and clear cells invasive cases was clearly significant (RR=20.9; CI= 5.08-148 
86.0) compared to serous EOC. Respect to the association of endometrial carcinoma 149 
with EOC, the result was also significant for the endometrioid and mix-endometrioid 150 
subtypes (25%). 151 
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Table 3 shows the clinical and pathologic characteristics of the EOC with or without 152 
associated endometriosis. Endometriosis-associated patients were significantly younger 153 
(48.8 versus 56.1 years old) and had lower parity. In these patients, there was a 154 
tendency to be premenopausal at the time of diagnosis, to have a lower-grade tumor 155 
according to FIGO classification and more borderline cases, and to have synchronous 156 
endometrial carcinoma. Moreover, they showed lower CA-125 values, although 157 
differences were not significant. In this sense, all endometriosis-associated EOC cases 158 
were type I according to the Kurman and Shih classification, and showed the best 159 
results in survival rates at 5 and 10 years (Kaplan-Meier method) (Figure 1) . 160 
When the 192 cases of EOC were reclassified according to Kurman and Shih´s 161 
classification, 109 were type I and 83 were type II tumors (Table 4). Comparing both 162 
groups, we observed clear significant differences: patients with type II EOC were older 163 
and had higher parity, were more frequently postmenopausal, showed higher CA-125 164 
levels and more advanced FIGO stages, and showed lower survival rates at 2, 5 and 10 165 
years (Figure 2). Moreover, there was a higher frequency (not significant) of breast 166 
cancer in this group, although a lower frequency of endometrial carcinoma. 167 
In table 4, the type I EOC are separated into: 1) low grade and borderline serous and all 168 
mucinous tumors, 2) endometrioid, and 3) clear cells carcinomas. No differences were 169 
observed between the subgroups 2 and 3 (which had more frequently associated 170 
endometriosis) respect to age, parity and FIGO stage. Blood sedimentation rate (BSR) 171 
values were significantly higher in clear cells carcinomas, whereas CA-125 and CA-19-172 
9 levels were higher in endometrioid EOC. As mentioned, these tumors showed a clear 173 
association with endometriosis and endometrial carcinoma and perhaps for this reason 174 
the survival rate was worse at 5 and 10 years.  175 
In order to analyze the possible pathologic progression among the subtypes of 176 
endometriosis and the endometrioid and clear cell EOC subtypes, Table 5 shows the 177 
clinical and pathologic characteristics of typical p53+ endometriosis, atypical 178 
endometriosis, endometrioid and clear cells (E/CC) carcinomas  with atypical or typical 179 
endometriosis, and E/CC carcinomas without associated endometriosis. Although there 180 
were no significant differences among groups because of the low number of cases in 181 
each one, the results showed that typical or atypical endometriosis were similar in all 182 
variables, but, when they were associated with an E/CC carcinoma, there was an 183 
increase in age, parity, BSR and tumor marker values. Moreover, the E/CC carcinomas 184 
without associated endometriosis had higher age, parity and tumor staging, and a lower 185 
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survival rate at 10 years. Therefore, it seems that the malignant transformation and 186 
progression evolved the next pathological order: 1. Endometriosis typical or atypical, 2. 187 
E/CC carcinomas with associated endometriosis and 3. Endometrioid or clear cell 188 
carcinomas.  189 
 190 
Discussion 191 
In this study, the percentage of patients with endometriosis-associated EOC among the 192 
total of EOC observed (20/192, 10.4%) was similar or superior that other recent 193 
publications: 10.9% (23/210) in Dzatic-Smiljkovic et al. [23]; 9.8% in Pearce et al. [24] 194 
(a pooled analysis of 13 case-control studies); or 7.5% (17/209) in Wang et al. [11]. But 195 
it was lower than other previous reports (11.2 to 29%) [14, 15, 25-27]. This variability 196 
may be the result of an under detection or missing reports of endometriosis in some 197 
centers, but a recent systematic review by Heidemann et al. [28] shows that some 198 
studies include all type of EOC and others only determined subtypes as endometrioid, 199 
clear cell, I-stage cases [29] (52.6%), or early stages [30] (23.7%). In fact, the 200 
association of endometriosis with EOC is more frequent in early stages and in 201 
determined histological types, mainly endometrioid and clear cell carcinomas, although 202 
there is also variability in results on the latter. Some studies report a predominant 203 
association with clear cell carcinomas [31]: 47% vs. 35% in endometrioid. Others [32] 204 
describe a higher association with endometrioid types, as observed in our results: 50% 205 
in endometrioid and mixed endometrioid, 23% in clear cells and mixed clear cells, 206 
versus 2.2-2.7% in serous or mucinous subtypes, or 0% in the type II tumors according 207 
to the Kurman and Shih’s classification [22]. Somigliana et al. [6] reviewed 11 studies 208 
about the frequency of endometriosis in ovarian cancer patients based on the 209 
histological type; the endometriosis-associated carcinoma was most commonly seen in 210 
clear cell carcinoma (35% of 390 cases), followed by endometrioid (27% of 648 cases), 211 
serous (5% of 1372 cases) and mucinous carcinoma (4% of 614 cases). These 212 
differences may be due to the group in which mixed tumors (endometrioid or clear 213 
cells) are included, because they are the most commonly associated with endometriosis. 214 
Furthermore, Song et al.[33] performed a retrospective review of 203 patients 215 
comparing endocervical-like versus intestinal-type mucinous borderline ovarían tumors 216 
and pointed that the first type had higher CA-125 and CA-19-9 levels and less relation 217 
to endometriosis (1.4%). 218 
Acién-8 
 
As mentioned above, the frequency in the association endometriosis-EOC also depends 219 
to the tumor staging. In our study, 50% of endometriosis-associated EOC cases were 220 
FIGO I-stage, and was also more common in low grade or borderline tumors. Several 221 
studies have reported a more benign character of the tumor when endometriosis is 222 
present [8-11, 29, 34, 35] with better survival rates (as shown in figure 1). Moreover, 223 
patients with endometriosis-associated EOC are younger, premenopausal, and have 224 
lower parity than those without endometriosis, so perhaps they are an intermediate stage 225 
in the pathological progression. Some authors [36, 37] have suggested that patients with 226 
a previous history of endometriosis should be followed up more closely, and then 227 
incidentally finding of early ovarian cancers would be more possible. However, the 228 
appearance is synchronous in most cases. Wang et al. [31] noted that only one of their 229 
patients had history of surgically identified endometriosis and, among our cases, only 2 230 
patients had previous surgically identified endometriosis. They are described in another 231 
article.  232 
On the other hand, atypical endometriosis is considered to be precancerous and strongly 233 
associated with endometriosis-associated ovarian cancer [16], although recognition of 234 
this form of endometriosis as a diagnostic criterion for pathological and clinical 235 
management remains controversial. Czernobilsky and Morris [12] first described 236 
atypical endometriosis, and Thomas and Campbell [20] further classified it based on the 237 
features that were identified in histological examinations. However, frequency of 238 
atypical endometriosis that is observed in EOC patients with associated endometriosis 239 
varies greatly between different series, from 3 to 12% [5] or up to 34% in EOC FIGO-I 240 
stage [15], with both types of endometriosis present in most of the same EOC cases (37 241 
of 127 EOC -29%-, having 33 typical and 29 atypical endometriosis). In this last study, 242 
the transition from typical to atypical endometriosis was observed in 22 cases, and the 243 
transition from atypical endometriosis to carcinoma was also observed in 23 cases, but a 244 
direct transition from typical endometriosis to carcinoma was observed in only 1 case 245 
[6, 15]. Besides, Ogawa et al. [15] described 43 patients who had clear cell carcinoma 246 
and only 7 cases of endometrioid carcinoma, which confirms the great variability that is 247 
found in the histological classifications, both in the subtype of carcinoma and the 248 
subtype of endometriosis. But it has to be taken into account that the prevalence                                                                                                                      249 
of clear cell EOC in Japan [34] seems to be much higher than that in western countries 250 
for unknown reasons. In our study, the few cases of atypical endometriosis that were 251 
associated with EOC were observed in endometrioid carcinomas, but no differences 252 
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were observed between typical (with or without p53 expression) and atypical 253 
endometriosis in the clinical variables analyzed. 254 
Ness [38] also reviewed the concept of endometriosis as a precursor lesion for ovarian 255 
cancer and proposed both inflammatory and hormonal pathways for this process. 256 
Estrogens seem to be a mitogen for both endometriosis and ovarian cancer [16] since 257 
most endometriotic tissues and several endometrioid carcinomas have a functional 258 
stroma and in situ estrogen production [39-41]. So, although there is evidence 259 
supporting a role for estrogens in the etiology of endometriosis and the enhancement of 260 
inflammation [42, 43], a plausible mechanism that links estrogens to ovarian 261 
carcinogenesis, as well as the steps for malignant transformation in ectopic 262 
endometrium has not yet been established.  263 
Moreover, many of the same genes, such as ß catenin and PTEN, have been shown to be 264 
mutated in both endometrial and endometrioid ovarian cancers, suggesting a shared 265 
molecular pathogenesis [36]. However, clear cell carcinomas do not express estrogen or 266 
progesterone receptors [444] and therefore endometriosis, that can transform into clear-267 
cell ovarian cancer, could became hormone independent during the transformation 268 
process [24, 45]. Therefore, an interesting dualistic model for the development of 269 
endometriosis-associated endometrioid EOC (with E and P receptor positive, and 270 
associated with hyperplastic aspects of the ectopic endometrium) and for endometriosis-271 
associated clear cell EOC (E and P receptor negative, and associated with iron-mediated 272 
oxidative stress) could be suggested [46, 47]. Synchronous endometrial-ovarian 273 
carcinomas are expected to be endometrioid hystotype, thus confirming the hormone-274 
dependent pathway. The clear cell ovarian histotype could arise from “atrophic” ectopic 275 
endometrium, similarly to the eutopic counterpart, not due to hyperplastic changes but 276 
rather repetitive DNA damage caused by iron-generated reactive oxygen species (the 277 
hormone-independent pathway) [48, 49]. Gounaris et al. [50] have questioned whether 278 
clear cell EOC is induced by “bad endometriosis” or “bad endometrium”. 279 
Molecular similarities between synchronous endometriosis and ovarian cancer at the 280 
time of diagnosis have been also described [38], but Pearce et al. [24] have pointed that 281 
would be also interesting to compare endometriotic lesion samples collected years ago 282 
to those obtained at the time of cancer diagnosis, because it might provide a basis for 283 
identification of women with endometriosis who are at highest risk of ovarian cancer, 284 
not forgetting that most of these patients do not develop EOC [24]. Although there is no 285 
evidence that surgery for endometriosis can reduce the risk of endometriosis-associated 286 
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EOC (clear cell/endometrioid/LG serous), various authors have reported this reduction 287 
observed in women with endometriosis-associated E/CC ovarian tumors [51] or among 288 
patients with endometriosis [52] who underwent ovarian surgery and radical extirpation 289 
of all visible endometriosis, suggesting therefore a preventive effect of this type of 290 
intervention. 291 
Respect to the endometrial-ovarian carcinoma synchrony, there are studies that have 292 
found no association between endometrial carcinoma and overall EOC or/and 293 
endometriosis [53, 54]. However, an interesting finding in our material was that 25% of 294 
endometrioid EOC were associated with a synchronous endometrial carcinoma, being in 295 
agree with other reports [55] which describe that approximately 90% of synchronous 296 
tumors that were identified in the ovary and in the endometrium were endometrioid cell 297 
type [56]. Two of our cases which associated endometriosis and borderline or malignant 298 
ovarian cancers had: endometrial carcinoma + ovarian endometrioid carcinoma + 299 
endometriosis, which was atypical in one of them. Similarly, Mangili et al [36] have 300 
found endometrial carcinoma in 33% of 21 cases of EOC with endometriosis, and in 301 
11% of 44 cases with EOC without endometriosis. This aspect has been indeed 302 
mentioned in the literature to describe clinical and pathological features of synchronous 303 
tumors, but there are few studies describing endometrial carcinoma and EOC with 304 
associated endometriosis [36, 56, 57]. These authors suggest the existence of a 305 
molecular, histological and clinical parallelism between endometrial carcinoma and 306 
endometrioid ovarian cancer that would be interesting in terms of prevention measures 307 
for ovarian cancers of endometrioid histotype. 308 
Summarizing, according to our results and the reviewed literature, it seems that, in 309 
certain endometriosis patients, the progression and pathological transformation to EOC 310 
may occur in the following order: 1. Endometriosis atypical or typical, 2. EOC 311 
(endometrioid/clear cell ovarian carcinoma) with associated endometriosis, and 3. 312 
Complete transformation into endometrioid (by hormonal and inflammatory effects due 313 
to recurrent episodes as hemorrhagic cysts) or clear cell carcinoma (by menses and 314 
acute inflammatory effects due to oxidative stress). Recently, Taniguchi et al. [34] have 315 
analysed the clinical characteristics of 33 patients diagnosed with ovarian cancer 316 
presumably arising from ovarian endometrioma. The diameter of the endometrioma and 317 
the preoperative CA-125 value did not significantly correlate. However, the authors 318 
concluded that to detect malignant transformation of ovarian endometrioma early and 319 
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precisely, the clinician should determine the existence of mural nodules and assess the 320 
rapid growth of the endometrioma. 321 
 322 
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TABLES 
Table 1. Epithelial ovarian cancers (EOC) with synchronous endometriosis and/or 
endometrial carcinoma. 
 
EOC N With associated 
endometriosis 
N (%), CI 
B vs. I cases 
RR, CI, P 
 
With endometrial 
carcinoma 
N (%), C.I. 
End vs. EC 
RR, CI, P 
 
Borderline 63 8 (12.7)* 
(0.066-0.231) 
- 5 (7.9)  
(0.034-0.172) 
RR 1.60  
(CI:0.55-4.62), NS 
Invasive 129 12 (9.3)** 
(0.054-0.156) 
RR 0.73  
(0.31-1.70), NS 
7 (5.4)  
(0.026-0.108) 
- 
Total 192 20 (10.4)  
(0.073-0.184) 
- 12 (6.25) (0.036-
0.106) 
RR 1.66  
(CI:0.83-3.31), NS 
 
N= number of cases; RR: relative risk; CI: confidence interval; B vs. I= borderline vs. 
invasive; EOC = end vs. EC (endometriosis vs. endometrial carcinoma). * 1 case and ** 
4 cases of atypical endometriosis. NS: not significant. 
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Table 2. Association between the histological type of epithelial ovarian cancer (EOC) 
and endometriosis, and with endometrial carcinoma. 
 
Associated endometriosis 
 
EOC n 
n (%) RR and CI 
Endometrial 
carcinoma, n (%) 
Serous: 
LG/borderline 
HG/Invasive 
91 
32 
59 
2 (2.2) 
2 (6.25) 
0  
(C) 
- 
- 
3 (3.2) 
 
Mucinous: 
Borderline 
Invasive 
37 
22 
15 
1 (2.7) 
1 (4.5 
0  
- 
- 
- 
1 (2.7) 
 
Endometrioid 
Borderline 
Invasive 
7 
3 
4 
5 (71.4) 
3* (100) 
2** (50) 
RR:32.5 
(CI:7.6-138.3) 
- 
2 (28.6) 
Mix with 
Endometrioid 
Borderline 
Invasive 
 
21 
3 
18 
 
9 (42.8) 
2 (66.6) 
7* (38.9) 
 
RR:19.5  
(CI:4.5-83.7) 
- 
 
5 (23.8) 
 
 
Clear cells 
Borderline 
Invasive 
9 
2 (1 mix) 
7 
3 (33.3) 
0  
3* (42.8) 
RR:17.1  
(CI:3.3-87.7) 
- 
0 
 
Mix, End+CC 
Borderline 
Invasive 
4 
1 
3 
0 
0 
0 
- 
 
1 (25) 
All clear cell EOC: 
3/13 (23.1%) 
  RR 10.5  
(CI:1.93-57.02) 
 
Endometrioid and 
clear cell EOC: 
17/37 (46%) 
  RR: 20.9 
(CI: 5.08-86.0) 
 
Other mix and 
undifferenciated 
23  
(3 carcinosarcomas) 
0  0  
 
(C) = considered as control group to statistical comparison; n= number of cases; CI= 
confidence interval; LG= low grade; HG= high grade; Mix, End+CC= mixed, 
endometrioid + clear cells; RR= relative risk compared with (C). * 1 and ** 2 atypical 
endometriosis. 
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Table 3. Clinical and pathologic characteristics of the epithelial ovarian cancer (EOC) 
with or without associated endometriosis. 
 
Variable EOC with 
endometriosis 
EOC without 
endometriosis 
RR(CI), p 
No. of cases 20 172 - 
Age, mean ± SD (range) 48.8 ± 11.6 (32-74) 56.1 ± 14.9 (21-88) <0.017 
Parity, % 
Null 
≥1 
 
10 (50) 
10 (50) 
 
46 (26.7) 
123 (71.5) 
 
0.53(0.32-0.88) 
Age of menopause, years 49.0 ± 5.01 49.1 ± 3.8 - 
Premenopause at the time of 
diagnosis, % 
 
11 (55) 
 
65 (37.8) 
 
0.68 (0.44-1.07), NS 
Age ≥50 years at the time of 
diagnosis, % 
 
9 (45) 
 
116 (67.4) 
 
1.49 (0.41-2.46), NS 
BSR 52.3 ± 39.7 [15] 31.8 ± 21.4 [79] <0.071 
CA-125 325.6 ± 376.2 [14] 533.6 ± 1081.7 [82] NS 
CA-19-9 275.6 ± 500.3 [13] 229.4 ± 851.7 [79] NS 
FIGO Stage, % 
I 
II 
III/IV 
 
10 (50) 
3 (15) 
7 (35) 
 
67 (39) 
19 (11) 
86 (50) 
 
NS 
Ovarian carcinoma, % 
Borderline 
Invasive 
 
8 (40) 
12 (60) 
 
55 (32) 
117 (68) 
 
NS 
Type (Kurman and Shih), % 
Type I 
Type II 
 
20 (100) 
0  
 
90 (52.3) 
82 (47.7) 
 
0.52(0.45-0.60) 
With synchronous endometrial 
carcinoma, % 
 
3 (15) 
 
9 (5.2) 
 
NS 
Survival (Kaplan-Meier) at, % 
2 years 
5 years 
      10 years 
[20] 
58 
58 
34.7 
[172] 
53 
31 
17.2 
 
NS 
0.53(0.35-0.83) 
0.49(0.25-0.98) 
 
BSR = blood sedimentation rate; [ ] = number of cases analyzed for these variables. 
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Table 4. Clinical and pathologic characteristics of the EOC, type I tumors (separating endometrioid and clear cells) versus type II tumors [22]. 
EOC, type I  
Variable LG and borderline 
serous and mucinous  
pure and mixed 
endometrioid 
Pure and mixed 
clear cells  
 
EOC, type II 
 
RR(CI), p 
(type II vs. type I) 
No. of cases 68 28 13 83  
Age, mean ± SD (MSE) 50.3 ± 16.8 (2.04) 53.9 ± 12.7 (2.4) 53.8 ± 15.3 (4.2) 60.1 ± 11.8 (1.3) <0.001 
Parity (64/57), % 
     Null 
     >1 
 
25 (37.3) 
42 (62.7) 
 
8 (28.6) 
20 (71.4) 
 
5 (38.5) 
8 (61.5) 
 
18 (21.7) 
65 (78.3) 
 
 
0.62 (0.38-1.01) 
Menopause at the time of 
diagnosis, % 
Premenopause 
Postmenopause 
 
 
38 (55.9) 
30 (44.1) 
 
 
11 (39.3) 
17 (60.7) 
 
 
5 (38.5) 
8 (61.5) 
 
 
22 (26.5) 
61 (73.5) 
 
 
 
0.53 (0.35-0.80) 
BSR 24.6 ± 18.1 (2.7) * 
[43] 
47.2 ± 30.7 (7.4) 
[17] 
80.4 ± 27.5 (12.3)* 
[5] 
38.2 ± 23.3 (3.9)  
[35] 
NS 
CA-125 148.1 ± 376.1 (58) 
[42] 
886.9 ± 1494.7 
(362) [17] 
228.6 ± 159.1 
(71.2) [5] 
803.8 ± 1201 (192) 
[39] 
<0.045 
CA-19-9 281.8 ± 1070 (165) 
[42] 
356.3 ± 625 (156) 
[16] 
63.7 ± 58.3 (26) 
[5] 
[36] 166.6 ± 517.4 
(86.2) 
NS 
Stage, % 
I/II 
III/IV 
 
57 (83.8) 
11 (16.2) 
 
16 (57.1) 
12 (42.8) 
 
9 (69.2) 
4 (30.8) 
 
17 (20.5) 
66 (79.5) 
 
 
0.27(0.17-0.42) 
Endometriosis, % 
Typical 
Atypical 
 
3 (4.4) (in BL) 
0  
 
10 (35.7) 
4 (14.3) 
 
2 (15.4) ** 
1 (7.7) 
 
0  
0  
 
15.2(2.08-111.2) 
Endometrial carcinoma, % 2 (2.9) 7 (25) 1 (7.7) 2 (2.4) NS 
Breast carcinoma, % 3 (4.4) 1 (3.6) 0  7 (8.4) NS 
Survival (Kaplan-Meier) at 
2 years 
5 years 
10 years 
 
78.8 
65.7 
65.7 
 
64.3 
42.9 
10.7 
 
57.2 
57.2 
57.2 + 
 
36.6 
12.8 
6.9 
 
0.51(0.38-0.69) 
0.22(0.12-0.40) 
0.21(0.09-0.47) 
[  ]: number of cases analysed in this variable; BSR= blood sedimentation rate; * significant differences CC vs. S/M.  ** significant differences 
E/CC versus S/M; + significant differences CC vs. endometrioid. 
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Table 5. Clinical and pathologic characteristics of atypical and typical endometriosis with p53+, associated or not with endometrioid and clear 
cell carcinomas 
 
Variable Endometriosis 
with p53+ 
Atypical 
endometriosis  
E/CC with atypical 
endometriosis  
E/CC with typical 
endometriosis 
E/CC without 
endometriosis 
RR, 
P 
 
No. of cases 17 30 5* 12 24  
Age, mean ± SD 
(MSE) 
36.1 ± 7.24 (1.7) 35.6 ± 8.7 (1.6) 48.6 ± 13.3 (5.93) 51.5 ± 11.1 (3.2) 56.3 ± 14.4 (2.9) NS 
Parity, % 
     Null 
     >1 
 
16 (94.1) 
1 (5.9) 
 
24 (80) 
6 (20) 
 
2 (40) 
3 (60) 
 
5 (41.7) 
7 (58.3) 
 
6 (25) 
18 (75) 
 
NS 
VS 18.9 ± 11 (2.75) 
[16] 
19.9 ± 11.7 (2.5) 
[22] 
632 ± 65 (32.5) 
[4] 
56.7 ± 25.6 (8.5) 
[9] 
49 ± 218 (73) 
[9] 
NS 
CA-125 66.3 ± 79.8 (19.9) 
[16] 
57.7 ± 28.1 (5.7) 
[24] 
188.7 ± 219.3 (109.7) 
[4] 
465.4 ± 431 (152) 
[8] 
1170 ± 1899 (600) 
[10] 
NS 
CA-19-9 21.9 ± 35.8 (9.6) 
[14] 
39.1 ± 49.1 (8.5) 
[24] 
67.4 ± 68.1 (34.04) 
[4] 
461.9 ± 640.5 (242.1) 
[7] 
246.3 ± 608 (192) 
[10] 
NS 
Stage, % 
I/II 
III/IV 
 
- 
 
- 
 
4 (80) 
1 (20) 
 
6 (50) 
6 (50) 
 
15 (62.5) 
9 (37.5) 
 
NS 
Endometrial 
carcinoma, % 
 
0 
 
0 
 
2 (40) 
 
1 (8.3) 
 
5 (20) 
 
NS 
Survival (Kaplan-
Meier) at , % 
2 years 
5 years 
10 years 
 
 
- 
 
 
- 
 
 
> 
 
 
50 
50 
30  
 
 
69.3 
54.5 
15.6 
 
 
NS 
NS 
NS 
*One case was an atypical endometrioid cystoadenoma; [ ]= number of cases analyzed in this variable; E/CC= endometrioid and clear cell 
carcinomas. 
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